Some Patients With Treatment-Resistant Colorectal Cancers May Have A New Option
6/02/2013
A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research...
Promising New Therapy For Lung Cancer
6/01/2013
A novel therapy for the most common form of lung cancer shows promise and seems to yield largely manageable side effects, according to new research that will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology...
What Is Warfarin?
6/01/2013
Warfarin is an anticoagulant medication - it is used to slow down the blood-clotting process. Anticoagulants are used to prevent blood clots which may cause vein blockages, heart attack and stroke. Warfarin is known under the brand names Warfant, Jantoven, Coumadin, Lawarin, Marevan, and Waran. Doctors prescribe warfarin for people who are at a higher risk of forming blood clots...
Father And Son To Present Their Respective Cancer Research At ASCO
6/01/2013
What started as a dinner-table conversation between a teen and his father has become a bonafide cancer research study for Matthew Lara, a Davis High School sophomore and the son of UC Davis Comprehensive Cancer Center medical oncologist and researcher Primo (Lucky) Lara...
Exposure To Dry-Cleaning Solvent And Degreaser TCE Linked To Increased Risk Of Some Cancers
6/01/2013
Trichloroethylene (TCE) exposure has possible links to increased liver cancer risk, and the relationship between TCE exposure and risks of cancers of low incidence and those with confounding by lifestyle and other factors need further study, according to a study published in the Journal of the National Cancer Institute...
Promising New Therapy For Lung Cancer
5/31/2013
A novel therapy for the most common form of lung cancer shows promise and seems to yield largely manageable side effects, according to new research that will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology...
Sensitizing Human Ovarian Cancer Cells To A Targeted Cytotoxic Drug
5/31/2013
A novel, targeted approach to chemotherapy that makes ovarian cancer cells more susceptible to the cytotoxic effects of an antitumor drug may offer a safer, more effective treatment option for this often deadly form of cancer. The research and results are published in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers...
Stem Cell Matrix -- A Summary Of Recent Studies From Harvard Stem Cell Institute
5/31/2013
May brought a major advancement in the science of aging when two Harvard Stem Cell Institute (HSCI) researchers announced their discovery of a protein circulating in the blood of mice and humans that shows potential to be a treatment for age-related heart failure. The protein, called GDF-11, reduced the size and thickness of the heart walls when injected into old mice...
Longer Treatment For Children With Langerhans Cell Hystiocytosis Improves Survival Rates
5/31/2013
A new international study finds that prolonged, intense initial treatment in children with multi-system Langerhans cell histiocytosis (MS-LCH) can achieve survival rates as high as 84 percent - a full 15 percent improvement over the previous clinical trial in this series. The study, LCH-III, is published in Blood, the journal of the American Society of Hematology...
For Patients With Stage III Lung Cancer, Higher-Dose RT Results In Inferior Survival
5/31/2013
In a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG), high-dose (HD), compared with standard-dose (SD), radiotherapy (RT) with concurrent chemotherapy (CT) did not improve overall survival of patients with stage III non-small-cell lung cancer (NSCLC)...